Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Use of Tolvaptan in Clinical Syndromes Characterized by Inappropriate Secretion of ADH
2010-022320-67Phase 3Active
- Sponsor
- Azienda Ospedaliero-Universitaria Maggiore della Carità
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tolvaptan in hyponatraemia and syndrome of inappropriate antidiuresis (SIAD), sponsored by Azienda Ospedaliero-Universitaria Maggiore della Carità. Primary endpoint: Correction of plasma sodium to normonatremia. Started Dec 2010; status: active.
02
Drugs
tolvaptan
03
Conditions
hyponatraemiasyndrome of inappropriate antidiuresis (SIAD)
Beyond the preview
Go deeper on 2010-022320-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022320-67.